RedHill Biopharma (RDHL) Registration Filing summary

Company overview and business model

• Specialty biopharmaceutical company focused on GI, infectious diseases, and oncology, with a goal to become a leading specialty biopharma firm.

• Commercializes Talicia® in the U.S. and advances a pipeline of five clinical-stage therapeutic candidates, including opaganib and RHB-107.

• Pursues global commercialization through licensing, co-development, and strategic partnerships.

Financial performance and metrics

• As of December 31, 2024, reported a stockholders' deficit of $4.7 million and did not meet Nasdaq's minimum equity requirement.

• Sold 890,001 ADSs for $3.3 million net proceeds via an ATM program in early 2025.

• Pro forma as adjusted capitalization after the offering would be $8.98 million in shareholders' equity, assuming full utilization of the equity line.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of ADSs by the selling shareholder; only proceeds from warrant exercises will be received.

• Any proceeds from warrant exercises will be used for general corporate purposes.

• No current intention to pay dividends; earnings will be reinvested in business development and expansion.